Charles River Laboratories International, Inc.’s Stock Price Tumbles to $224.75, marking a 3.36% Drop: Unpacking the Performance

Charles River Laboratories International, Inc. (CRL)

224.75 USD -7.81 (-3.36%) Volume: 1.3M

Charles River Laboratories International, Inc.’s stock price stands at 224.75 USD, experiencing a dip of -3.36% this trading session with a trading volume of 1.3M, reflecting a YTD performance decrease of -4.93%, indicating a cautious market sentiment towards CRL.

Latest developments on Charles River Laboratories International, Inc.

Recent events have influenced the stock price movements of Charles River Laboratories International, Inc. (NYSE:CRL) today. The company’s EVP, Joseph Laplume, made a significant sale of over $295,000 in company stock, while M&T Bank Corp decreased its stake in the company. Additionally, Apollon Wealth Management LLC disclosed a substantial holding in Charles River Laboratories International. Despite concerns over capacity and supply chain issues, the company reported earnings that beat expectations for the full year 2022. These developments have impacted the stock price target, which was lowered to $228.00. Insider selling and updates in lawsuits have also contributed to the fluctuations in Charles River Laboratories International’s stock price today.

A look at Charles River Laboratories International, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Charles River Laboratories International, Inc. provides research tools and support services for drug discovery and development. The company offers animal research models needed for developing new drugs, devices, and therapies. With a Smartkarma Smart Score indicating a strong momentum and growth outlook, Charles River Laboratories seems to be well-positioned for long-term success in the industry.

Although the company’s dividend and resilience scores are lower, its value and growth scores are moderate. Charles River Laboratories serves a diverse customer base, including pharmaceutical and biotechnology companies, hospitals, and academic institutions. Overall, the company’s favorable momentum score suggests that it may continue to experience positive performance and expansion in the future.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma